-
1
-
-
12144258439
-
The emerging normal and disease-related roles of anaplastic lymphoma kinase
-
Pulford K, Lamant L, Espinos E, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61:2939-53.
-
(2004)
Cell Mol Life Sci
, vol.61
, pp. 2939-2953
-
-
Pulford, K.1
Lamant, L.2
Espinos, E.3
-
2
-
-
0036731704
-
Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma
-
Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J ClinOncol. 2002;20:3691-702.
-
(2002)
J ClinOncol
, vol.20
, pp. 3691-3702
-
-
Kutok, J.L.1
Aster, J.C.2
-
3
-
-
54049120220
-
Activating mutations in ALK provide atherapeutic target in neuroblastoma
-
George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide atherapeutic target in neuroblastoma. Nature. 2008;455:975-8.
-
(2008)
Nature
, vol.455
, pp. 975-978
-
-
George, R.E.1
Sanda, T.2
Hanna, M.3
-
4
-
-
54049094708
-
Identification of ALK as a major familial neuroblastoma predisposition gene
-
Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930-5.
-
(2008)
Nature
, vol.455
, pp. 930-935
-
-
Mossé, Y.P.1
Laudenslager, M.2
Longo, L.3
-
5
-
-
0028198206
-
Fusion of a kinase gene, ALK, to a nucleolar protein gene NPM, in non-Hodgkins lymphoma
-
Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene NPM, in non-Hodgkins lymphoma. Science. 1994; 263:1281-4.
-
(1994)
Science
, vol.263
, pp. 1281-1284
-
-
Morris, S.W.1
Kirstein, M.N.2
Valentine, M.B.3
-
6
-
-
0031008896
-
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkins lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
-
Morris SW, Naeve C, Matthew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkins lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14:2175-88.
-
(1997)
Oncogene
, vol.14
, pp. 2175-2188
-
-
Morris, S.W.1
Naeve, C.2
Matthew, P.3
-
7
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer
-
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007;448:561-6.
-
(2007)
Nature
, vol.448
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
-
8
-
-
34948834758
-
Pathobiology of ALK+ anaplastic large cell lymphoma
-
Amin HM, Lai R. Pathobiology of ALK+ anaplastic large cell lymphoma. Blood. 2007;110:2259-67.
-
(2007)
Blood
, vol.110
, pp. 2259-2267
-
-
Amin, H.M.1
Lai, R.2
-
9
-
-
48549098388
-
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
-
Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008;68:4971-6.
-
(2008)
Cancer Res
, vol.68
, pp. 4971-4976
-
-
Choi, Y.L.1
Takeuchi, K.2
Soda, M.3
-
10
-
-
78650950138
-
EGFR and EML4-ALK mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
-
Tiseo M, Gelsomino F, Boggiani D, et al. EGFR and EML4-ALK mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 2011;71:241-3.
-
(2011)
Lung Cancer
, vol.71
, pp. 241-243
-
-
Tiseo, M.1
Gelsomino, F.2
Boggiani, D.3
-
11
-
-
70349336416
-
Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK
-
Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-53.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4247-4253
-
-
Shaw, A.T.1
Yeap, B.Y.2
Mino-Kenudson, M.3
-
12
-
-
69349083935
-
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western populations
-
Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western populations. Clin Cancer Res. 2009;15:5216-23.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5216-5223
-
-
Rodig, S.J.1
Mino-Kenudson, M.2
Dacic, S.3
-
13
-
-
77649091118
-
A novel highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
-
Mino-Kenudson M, Chirieac LR, Law K, et al. A novel highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16:1561-71.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1561-1571
-
-
Mino-Kenudson, M.1
Chirieac, L.R.2
Law, K.3
-
14
-
-
37549059613
-
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma
-
Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma. Mol Cancer Ther. 2007;3314-22.
-
(2007)
Mol Cancer Ther
, pp. 3314-3322
-
-
Christensen, J.G.1
Zou, H.Y.2
Arango, M.E.3
-
15
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small cell lung cancer
-
Kwak EL, Bang Y-J, Camidge R, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med. 2010;363:1693-1703.
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.-J.2
Camidge, R.3
-
16
-
-
64649091718
-
Meta-analysis of single agent chemotherapy compared with combination chemotherapy as second line treatment for advanced non-small cell lung cancer
-
Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single agent chemotherapy compared with combination chemotherapy as second line treatment for advanced non-small cell lung cancer. J Clin Oncol. 2009;27:1836-43.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1836-1843
-
-
di Maio, M.1
Chiodini, P.2
Georgoulias, V.3
-
17
-
-
78049426513
-
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
-
Choi YL, Soda M, Tanio Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734-9.
-
(2010)
N Engl J Med
, vol.363
, pp. 1734-1739
-
-
Choi, Y.L.1
Soda, M.2
Tanio, Y.3
-
18
-
-
79960250811
-
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors
-
May 25 [Epub ahead of print]
-
Lovly CM, Heuckmann JM, de Stanchina E, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011; May 25 [Epub ahead of print]
-
(2011)
Cancer Res
-
-
Lovly, C.M.1
Heuckmann, J.M.2
de Stanchina, E.3
-
19
-
-
79957896979
-
The HSP90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models
-
Jan 24 [Epub ahead of print]
-
Normant E, Paez G, West KA, et al. The HSP90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 2011;Jan 24 [Epub ahead of print]
-
(2011)
Oncogene
-
-
Normant, E.1
Paez, G.2
West, K.A.3
|